Name

YourChoice Therapeutics

Legal name

Your Choice Therapeutics

Website

https://www.yourchoicetx.com/

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Male Contraceptive Pharmaceuticals

akta.pro primary industry

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ)

akta.pro secondary industry

Sexual & Reproductive Health & Family Planning (SRH/FP) Programs (BPADAIAD)

Keywords

• Non-hormonal contraception
• Male contraceptive pill
• Retinoic acid antagonist
• Clinical-stage biotech
• Oral contraceptive drug

Headquarters

HQ city

Berkeley

HQ country

United States

HQ region

North America

Offices2 records

Markets served

GTM type

B2C

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Pharmaceutical product revenue: Once YCT-529 receives regulatory approval (FDA and international equivalents), the company plans to commercialize the male contraceptive pill through partnership with larger pharmaceutical companies. Revenue will come from product sales following successful clinical trials and regulatory approval.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels4 records

Core offering

YourChoice Therapeutics is developing YCT-529, an investigational oral, non-hormonal male contraceptive pill designed to be taken daily. YCT-529 selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones, with preclinical evidence of reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is not yet approved by any regulatory authority.

Product overview

YourChoice Therapeutics is developing a single core product, YCT-529, an oral non-hormonal male contraceptive pill. The company is a San Francisco Bay Area biotech that licensed the technology from the University of Minnesota in 2021. YCT-529 is currently in Phase 2 clinical trials and works by selectively blocking retinoic acid receptor-alpha (RAR-alpha), a receptor essential for sperm production. The product is designed to be daily-use, reversible, and hormone-free, addressing the unmet need for male contraceptive options beyond condoms or vasectomy.

Differentiator

Problem solved

Functional benefit

Products and services

• YCT-529 Investigational oral, non-hormonal male contraceptive pill that selectively blocks retinoic acid receptor-alpha (RAR-alpha) to temporarily halt sperm production while preserving testosterone, libido, and other reproductive hormones; preclinical data indicate reversibility after discontinuation. The product is currently in Phase 2 clinical trials and is intended for adult men seeking a reversible contraceptive option beyond condoms or vasectomy.

Quantifiable outcome

• No serious adverse events reported in Phase 1a trial with 16 healthy male volunteers
• +3 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Three partnerships are on record, tiered core and minor.

• University of MinnesotacoreStrategic or Co-development Partner · 1 January 2021YourChoice Therapeutics licensed the YCT-529 technology from the University of Minnesota in 2021. Researchers at the university developed the non-hormonal male birth control pill after a decade of research targeting the retinoic acid pathway needed for sperm production. The company is now sponsoring the drug's clinical trials.
• Quotient SciencescoreStrategic or Co-development PartnerQuotient Sciences conducted the Phase 1 clinical trial of YCT-529 at their Phase 1 unit in Nottingham, UK. The trial involved 16 healthy vasectomized men aged 32-59 years to establish safety and pharmacokinetics of the non-hormonal male contraceptive pill.
• ContracealineminorOthersContracealine is mentioned alongside YourChoice Therapeutics as advancing male contraceptive candidates in the development pipeline. YCT-529 is identified as a leading candidate in clinical development alongside NES/T and ADAM. No formal partnership relationship indicated.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Contraline: Clinical-stage company developing a long-acting, non-hormonal male contraceptive (ADAM, a hydrogel injection into the vas deferens). Directly comparable as another developer of novel non-hormonal male contraceptive products advancing in clinical trials.

Emerging players

• NEXT Life Sciences: Developer of Plan A, a long-acting reversible male contraceptive targeting the vas deferens. Comparable as an emerging player in the male contraceptive space pursuing non-hormonal, reversible solutions with a different delivery mechanism than YCT-529.
• Eppin Pharma: Early-stage biotech developing a non-hormonal male contraceptive targeting the sperm surface protein EPPIN. Comparable as a developer of novel mechanism, non-hormonal male contraceptives working toward clinical proof-of-concept.
• Dare Bioscience: Clinical-stage biopharmaceutical company focused on women's reproductive health with a portfolio of contraceptive candidates. Comparable as a similarly-sized clinical-stage company developing innovative reproductive health products through partnership-driven commercialization.
• Agile Therapeutics: Women's health pharmaceutical company developing hormonal contraceptive products. Comparable as a small-cap clinical-stage reproductive health pharmaceutical company that has navigated FDA approval and commercialization of contraceptive products.

Others

• Male Contraceptive Initiative: Non-profit advocacy and funding organization actively investing in the male contraceptive pipeline, including a grant to YourChoice Therapeutics. Comparable as a key ecosystem participant shaping the male contraceptive development landscape and funding peer companies.
• Population Council: International non-profit research organization developing multiple contraceptive technologies, including non-hormonal approaches. Comparable as an ecosystem participant advancing the broader male contraceptive pipeline through research and clinical development.

Broad incumbents

• Organon & Co. Global women's health pharmaceutical company with a portfolio of established contraceptive products. Comparable as a broad incumbent in reproductive health pharmaceuticals and a likely potential commercialization/acquisition partner for YCT-529.
• Bayer (Pharmaceuticals): Major pharmaceutical company with a leading contraceptive franchise (Mirena, Yaz, etc.) and history of investing in reproductive health R&D. Comparable as a broad incumbent with contraceptive commercialization capabilities and a potential partner for male contraceptive assets.
• Pfizer: Large pharmaceutical company with established contraceptive products and prior male contraceptive research investments. Comparable as a broad incumbent that has historically been active in male contraceptive research and is a potential strategic acquirer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds7 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about YourChoice Therapeutics